Systematic review: continuous intraperitoneal insulin infusion with implantable insulin pumps for diabetes mellitus
Abstract
Unlabelled Continuous intraperitoneal insulin infusion (CIPII) with implantable insulin pumps (IIPs) is a treatment option for diabetes, which is not widely utilized nor freely accessible in clinical practice. The aim of this study was to summarize available evidence on use of IIPs for CIPII for diabetes treatment, since its introduction to clinical use on the following outcomes: HbA1c, hypoglycaemic events, and complications of treatment. Secondary outcomes complications of diabetes and treatment satisfaction. Following the procedure for a systematic review this paper may contribute to a balanced evaluation of the need and effectiveness of IIPs. A pre-specified, registered protocol (CRD42012002150) was followed. Studies investigating all diabetes populations and types of IIPs were considered eligible. The sensitive search strategy was developed in collaboration with a clinical librarian and contents experts. PUBMED, MEDLINE, CENTRAL EMBASE, trial registries, and other databases were searched. References were screened independently by two authors, and decisions on study selection were recorded. Of the 1,703 references screened, 362 were assessed as potentially eligible. Ninety-four were identified as studies using IIPs. Fifteen papers, together reporting on four-randomized trials, and eight cohorts were included. Narrative analysis is provided, and data tables are available. CIPII by way of IIPs is effective in lowering HbA1c levels and reducing hypoglycaemic events. Superior…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Compared with subcutaneous insulin regimens, intraperitoneal insulin infusion reduces HbA1c, glycemic variability, and hypoglycemia.
“Compared with subcutaneous insulin regimens, intraperitoneal insulin infusion reduces HbA 1c , glycemic variability, and hypoglycemia (98,99).”
Cites
Diagnosis and classification of diabetes mellitus
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s067 · Cited by 2,245 · see citing works
Glucose Variability; Does It Matter?
Siegelaar, S. E., Holleman, F., Hoekstra, J. B. L., & DeVries, J. H. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0021 · Cited by 409 · see citing works
Evolution of Devices in Diabetes Management
Penfornis, A., Personeni, E., & Borot, S. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0058 · Cited by 49 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Holt, R. I. G., DeVries, J. H., Fischl, A. H., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, É., et al. (2021) · Diabetologia · doi:10.1007/s00125-021-05568-3 · Cited by 427 · see citing works
Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetes Care · doi:10.2337/dci21-0043 · Cited by 699 · see citing works
“Compared with subcutaneous insulin regimens, intraperitoneal insulin infusion reduces HbA1c, glycemic variability, and hypoglycemia (98,99).”
Dassau, E., Renard, E., Place, J., Farret, A., Pelletier, M., Lee, J., Huyett, L. M., Chakrabarty, A., Doyle, F. J., & Zisser, H. C. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12999 · Cited by 94 · see citing works
“Of note, even in open-loop mode, IP insulin infusion from implantable insulin pumps has been reported as allowing lower HbA1c levels than CSII.27 IP infusion using the DiaPort system was not shown to reduce HbA1c levels significantly as compared with CSII, but occurrence of severe hypoglycaemia was dramatically reduce…”
MethodInfluentialOral Insulin Delivery in a Physiologic Context: Review
Arbit, E., & Kidron, M. (2017) · Journal of Diabetes Science and Technology · doi:10.1177/1932296817691303 · Cited by 77 · see citing works
Boscari, F., & Avogaro, A. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09635-3 · Cited by 65 · see citing works
Structural principles of insulin formulation and analog design: A century of innovation
Jarosinski, M., Dhayalan, B., Chen, Y.-S., Chatterjee, D., Varas, N., & Weiss, M. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101325 · Cited by 46 · see citing works
“Such engineering efforts are continuing, as exemplified by implanted intraperitoneal pumps [133,134] and inhalation devices for insulin powders [130].”
Backgroundl-Valine appended PLGA nanoparticles for oral insulin delivery
Jain, A., & Jain, S. (2015) · Acta Diabetologica · doi:10.1007/s00592-015-0714-3 · Cited by 41 · see citing works
“There are many devices available in the literature to deliver insulin through various routes, and they all are having some implications on patients [3–6].”
BackgroundHuyett, L., Dassau, E., Zisser, H., & Doyle, F. J. (2018) · IEEE Control Systems · doi:10.1109/mcs.2017.2766322 · Cited by 39 · see citing works
“Insulin delivery through the IP route has been shown to reduce the frequency of hypoglycemic episodes and improve the glycemic control of people with T1DM [28]–[30].”
BackgroundNanomedicines based on trace elements for intervention of diabetes mellitus.
Ruan, S., Guo, X., Ren, Y., Cao, G.-S., Xing, H., & Zhang, X.-W. (2023) · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · doi:10.1016/j.biopha.2023.115684 · Cited by 26 · see citing works
Dirnena-Fusini, I., Åm, M. K., Fougner, A., Carlsen, S., & Christiansen, S. C. (2021) · PLoS ONE · doi:10.1371/journal.pone.0249611 · Cited by 16 · see citing works
“Interestingly, and probably as a consequence of the study objectives, none of the studies included in our own systematic review were included in those two previous systematic reviews [66, 67].”
Treatment with continuous subcutaneous insulin infusion is associated with lower arterial stiffness
Rosenlund, S., Theilade, S., Hansen, T., Andersen, S., & Rossing, P. (2014) · Acta Diabetologica · doi:10.1007/s00592-014-0619-6 · Cited by 15 · see citing works
“The primary method of CII is continuous subcutaneous insulin infusion (CSII); however, a very limited number of patients receive intraperitoneal insulin infusion [1].”
MethodImplantable insulin pumps: an effective option with restricted dissemination.
Spaan, N., Teplova, A. E., Renard, E., & Spaan, J. (2014) · The Lancet Diabetes and Endocrinology · doi:10.1016/s2213-8587(14)70035-x · Cited by 14 · see citing works
Self-citationHe, J., Renard, É., Lord, P., Cohen, D., Cem-Duranty, E., Place, J., Gu, B., Wang, X., Yenduri, G., & Burgess, D. J. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.06.005 · Cited by 13 · see citing works
A New Optimized Percutaneous Access System for CIPII
Garcı́a-Verdugo, R., Erbach, M., & Schnell, O. (2017) · Journal of Diabetes Science and Technology · doi:10.1177/1932296817694913 · Cited by 10 · see citing works
Teigen, I. A., Åm, M. K., Carlsen, S., & Christiansen, S. C. (2021) · European journal of drug metabolism and pharmacokinetics · doi:10.1007/s13318-021-00692-2 · Cited by 8 · see citing works
“Insulin pumps with IP delivery have been tested on humans with some success [19, 20].”
BackgroundAutomated Insulin Delivery—The Light at the End of the Tunnel
Turksoy, K., Frantz, N., Quinn, L., Dumin, M., Kilkus, J., Hibner, B., Çinar, A., & Littlejohn, E. (2017) · Jornal de Pediatria · doi:10.1016/j.jpeds.2017.02.055 · Cited by 8 · see citing works
Fonnes, S., Holzknecht, B., Arpi, M., & Rosenberg, J. (2017) · Drug Research · doi:10.1055/s-0043-109565 · Cited by 7
“Finally, it has been used to administer insulin in diabetes mellitus, where it seems to improve glycaemic control for some subgroups of patients [7, 8].”
MethodSteyn, L., Drew, D. A., Vlachos, D. A., Huey, B. L., Cocchi, K., Price, N. D., Johnson, R. C., Putnam, C. W., & Papas, K. (2022) · medRxiv · doi:10.1371/journal.pone.0278794 · Cited by 5 · see citing works
The Evolution of Insulin Administration in Type 1 Diabetes
Pinnaro, C. T., & Tansey, M. (2021) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2021.115021 · Cited by 7 · see citing works
“Intraperitoneal insulin using implantable pumps or percutaneous port systems is indicated when subcutaneous or inhaled routes are not possible or effective, although this is not widely available outside of Europe [22] [23].”
BackgroundLee, S., & Narendran, P. (2014) · BMJ Case Reports · doi:10.1136/bcr-2014-205278 · Cited by 5
Approaches to the Development of Implantable Therapeutic Systems
Mane, A., Maheshwari, N., Ghode, P., Sharma, M. C., & Tekade, R. (2019) · Biomaterials and Bionanotechnology · doi:10.1016/b978-0-12-814427-5.00006-8 · Cited by 5 · see citing works
Tonolo, G., DeMonte, A., Taras, M. A., Scorsone, A., Tatti, P., Pittui, B., Turco, S., & Trentin, R. (2024) · Diabetology · doi:10.3390/diabetology5030021 · Cited by 4 · see citing works
“This method has been applied with subcutaneous insulin pumps delivering insulin directly in the peritoneum [62] or by the use of external pumps connected through a port to the peritoneal space (DiaPort) crossing the skin to the peritoneum [63].”
MethodChatterjee, S., Sharma, C., Lavie, C., Adhikari, A., Deedwania, P., & O'Keefe, J. (2020) · Minerva Endocrinologica · doi:10.23736/s0391-1977.19.03055-4 · Cited by 3 · see citing works
Surgical options for glycaemic control in Type 1 diabetes
Yeung, K., Reddy, M., & Purkayastha, S. (2019) · Diabetic Medicine · doi:10.1111/dme.13885 · Cited by 2 · see citing works
“For those recipients with a functioning graft at one-year post-transplant, the five-year graft survival is 60 (42-74) % for those recipients who receive an additional priority islet graft and 44 (24-62) % for those who do not.”
BackgroundHidefjäll, P., & Backheden, M. (2017) · Health Policy and Technology · doi:10.1016/j.hlpt.2017.04.005 · Cited by 2 · see citing works
Åm, M. K., Teigen, I. A., Riaz, M., Fougner, A. L., Christiansen, S. C., & Carlsen, S. M. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02193-2 · Cited by 7 · see citing works
“Additionally, IP insulin delivery is hampered by several challenges, such as occlusion of the insulin delivery line, which has been reported in several trials of IP insulin delivery and infection at the site of the abdominal port [67].”
BackgroundZhang, N., McNeil, E. B., Assanangkornchai, S., & Fan, Y. (2016) · F1000Research · doi:10.12688/f1000research.9095.1 · Cited by 1 · see citing works
Implantable drug delivery devices
Chappel, E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819838-4.00001-8 · Cited by 1 · see citing works
NEW FORMS AND TECHNOLOGIES OF INSULIN THERAPY IN TYPE 1 DIABETES - A SYSTEMATIC LITERATURE REVIEW
Ogórek, A., Kaniak, A., Andrzejewska, J., Wińska, A., Pietruszewska, H., Czerepak, I., Majchrzak, I., Ziemba, M., Zackiewicz, K., & Zielska, J. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4479
Glucose control with non-insulin based therapies for type 1 diabetes
Narendran, P., & Smyth, T. (2016) · Nurse Prescribing · doi:10.12968/npre.2016.14.1.24
Research Hotspots Analysis of Insulin by PubMed
Hou, J.-J., & Gu, C. (2015) · International Conference on Information Technology in Medicine and Education · doi:10.1109/itme.2015.153
“Diabetes is permanent illness, insulin therapy is a treatment for a long time, especially in patients with type 1 diabetes, and even multiple doses a day, with the progress of technology, the traditional hypodermic is gradually replaced by a more convenient, less pain, good curative effect method of subcutaneous drug…”
Background
- Authors
- Spaan, N., Teplova, A., Stam, G., Spaan, J., & Lucas, C.
- Affiliations
- University of Applied Sciences Leiden (NL)
- Sophia Revalidatie (NL)
- Amsterdam UMC Location University of Amsterdam (NL)
- Corresponding author
- Spaan, Nienke
- Venue
- Acta Diabetologica
- Published
- 2014-03-05
- Volume
- 51
- Issue
- 3
- Pages
- 339-351
- ISSN
- 0940-5429 (ISSN-L)
- 1432-5233
- OpenAlex
- W1995122389
- Cited by
- 46
- References
- 0
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 3 · 2023: 3 · 2022: 3 · 2021: 9 · 2020: 3 · 2019: 3 · 2018: 4 · 2017: 6 · 2016: 3 · 2015: 4 · 2014: 3
- FWCI
- 0.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Acta Diabetologica (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- implantable insulin pump, diabetes mellitus, glycemic control, HbA1c, hypoglycemia, diabetes complications, treatment satisfaction, quality of life
- MeSH terms
- Animals, Clinical Trials as Topic, Diabetes Mellitus, Humans, Hypoglycemic Agents, Infusions, Parenteral, Insulin, Insulin Infusion Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
